Jean Donadieu

List of Publications by Year
in descending order

128 papers	12,037 citations	30070 54 h-index	27406 106 g-index
134 all docs	134 docs citations	134 times ranked	10294 citing authors

#	Article	IF	Citations
1	Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood, 2016, 127, 2672-2681.	1.4	1,040
2	B cellâ€“helper neutrophils stimulate the diversification and production of immunoglobulin in the marginal zone of the spleen. Nature Immunology, 2012, 13, 170-180.	14.5	615
3	High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood, 2012, 120, 2700-2703.	1.4	589
4	Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical workâ€up, and treatment for patients till the age of 18 years. Pediatric Blood and Cancer, 2013, 60, 175-184.	1.5	496
5	Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood, 2013, 121, 1495-1500.	1.4	479
6	Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms. Cancer Discovery, 2016, 6, 154-165.	9.4	372
7	Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood, 2013, 121, 5006-5014.	1.4	343
8	Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood, 2018, 131, 2877-2890.	1.4	335
9	Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood, 2008, 111, 2556-2562.	1.4	287
10	Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000â€“2004. Pediatric Blood and Cancer, 2008, 51, 71-75.	1.5	248
11	Uncoupling of GTP hydrolysis from eIF6 release on the ribosome causes Shwachman-Diamond syndrome. Genes and Development, 2011, 25, 917-929.	5.9	247
12	Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAF^{V600E}-Mutated Erdheim-Chester Disease. Journal of Clinical Oncology, 2015, 33, 411-418.	1.6	238
13	Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group. Haematologica, 2005, 90, 45-53.	3.5	234
14	BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy. Journal of Clinical Oncology, 2016, 34, 3023-3030.	1.6	233
15	Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood, 2014, 124, 1119-1126.	1.4	208
16	Neutrophil depletion impairs natural killer cell maturation, function, and homeostasis. Journal of Experimental Medicine, 2012, 209, 565-580.	8.5	199
17	Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood, 2014, 124, 3016-3019.	1.4	197
18	High frequency of GATA2 mutations in patients with mild chronic neutropenia evolving to MonoMac syndrome, myelodysplasia, and acute myeloid leukemia. Blood, 2013, 121, 822-829.	1.4	189

#	Article	IF	Citations
19	Mutations in the ELA2 gene correlate with more severe expression of neutropenia: a study of 81 patients from the French Neutropenia Register. Blood, 2004, 103, 4119-4125.	1.4	187
20	Draft consensus guidelines for diagnosis and treatment of Shwachmanâ€Diamond syndrome. Annals of the New York Academy of Sciences, 2011, 1242, 40-55.	3.8	183
21	Endocrine involvement in pediatric-onset langerhans' cell histiocytosis: a population-based study. Journal of Pediatrics, 2004, 144, 344-350.	1.8	181
22	Analysis of a French cohort of patients with large granular lymphocyte leukemia: a report on 229 cases. Haematologica, 2010, 95, 1534-1541.	3.5	176
23	Congenital neutropenia: diagnosis, molecular bases and patient management. Orphanet Journal of Rare Diseases, 2011, 6, 26.	2.7	173
24	Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncology, The, 2017, 18, e113-e125.	10.7	154
25	Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood, 2017, 130, 1377-1380.	1.4	146
26	The Severe Chronic Neutropenia International Registry: 10-Year Follow-up Report. Supportive Cancer Therapy, 2006, 3, 220-231.	0.3	135
27	Cooperativity of RUNX1 and CSF3R mutations in severe congenital neutropenia: a unique pathway in myeloid leukemogenesis. Blood, 2014, 123, 2229-2237.	1.4	135
28	B-RAF Mutant Alleles Associated with Langerhans Cell Histiocytosis, a Granulomatous Pediatric Disease. PLoS ONE, 2012, 7, e33891.	2.5	132
29	Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Journal of Clinical Oncology, 2019, 37, 2857-2865.	1.6	132
30	Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients. Haematologica, 2018, 103, 1278-1287.	3.5	129
31	Classification of and risk factors for hematologic complications in a French national cohort of 102 patients with Shwachman-Diamond syndrome. Haematologica, 2012, 97, 1312-1319.	3.5	120
32	JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nature Genetics, 2014, 46, 1021-1027.	21.4	119
33	Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood, 2015, 126, 1415-1423.	1.4	117
34	Congenital neutropenia in the era of genomics: classification, diagnosis, and natural history. British Journal of Haematology, 2017, 179, 557-574.	2.5	115
35	2â€²â€chlorodeoxyadenosine (2â€CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCHâ€Sâ€98 protocol of the histiocyte society. Pediatric Blood and Cancer, 2009, 53, 1271-1276.	1.5	97
36	Description and outcome of a cohort of 8 patients with WHIM syndrome from the French Severe Chronic Neutropenia Registry. Orphanet Journal of Rare Diseases, 2012, 7, 71.	2.7	96

#	Article	IF	Citations
37	Incidence of Growth Hormone Deficiency in Pediatric-Onset Langerhans Cell Histiocytosis: Efficacy and Safety of Growth Hormone Treatment. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 604-609.	3.6	95
38	Phenotypes and survival in Erdheimâ€Chester disease: Results from a 165â€patient cohort. American Journal of Hematology, 2018, 93, E114-E117.	4.1	94
39	Natural history of Barth syndrome: a national cohort study of 22 patients. Orphanet Journal of Rare Diseases, 2013, 8, 70.	2.7	93
40	Vemurafenib Use in an Infant for High-Risk Langerhans Cell Histiocytosis. JAMA Oncology, 2015, 1, 836.	7.1	92
41	Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood, 2007, 110, 1648-1655.	1.4	88
42	Reactivations in Multisystem Langerhans Cell Histiocytosis: Data of the International LCH Registry. Journal of Pediatrics, 2008, 153, 700-705.e2.	1.8	88
43	Medical management of langerhans cell histiocytosis from diagnosis to treatment. Expert Opinion on Pharmacotherapy, 2012, 13, 1309-1322.	1.8	86
44	Mutations in the SRP54 gene cause severe congenital neutropenia as well as Shwachman-Diamondâ€“like syndrome. Blood, 2018, 132, 1318-1331.	1.4	85
45	Langerhans cell histiocytosis: therapeutic strategy and outcome in a 30â€year nationwide cohort of 1478 patients under 18Âyears of age. British Journal of Haematology, 2016, 174, 887-898.	2.5	83
46	A New clinical score for disease activity in Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2004, 43, 770-776.	1.5	82
47	Prevention of Infections During Primary Immunodeficiency. Clinical Infectious Diseases, 2014, 59, 1462-1470.	5.8	81
48	Epigenetic Regulation of Protein-Coding and MicroRNA Genes by the Gfi1-Interacting Tumor Suppressor PRDM5. Molecular and Cellular Biology, 2007, 27, 6889-6902.	2.3	79
49	Cohen syndrome is associated with major glycosylation defects. Human Molecular Genetics, 2014, 23, 2391-2399.	2.9	79
50	Stem cell transplantation in severe congenital neutropenia: an analysis from the European Society for Blood and Marrow Transplantation. Blood, 2015, 126, 1885-1892.	1.4	76
51	Dramatic response of a BRAF V600E-mutated primary CNS histiocytic sarcoma to vemurafenib. Neurology, 2014, 83, 1478-1480.	1.1	70
52	Extended Spectrum of Human Glucose-6-Phosphatase Catalytic Subunit 3 Deficiency: Novel Genotypes and Phenotypic Variability in Severe Congenital Neutropenia. Journal of Pediatrics, 2012, 160, 679-683.e2.	1.8	67
53	Langerhans Cell Histiocytosis and the Central Nervous System in Childhood: Evolution and Prognostic Factors. Results of a Collaborative Study. Journal of Child Neurology, 2000, 15, 150-156.	1.4	63
54	ALK-positiveÂhistiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood, 2022, 139, 256-280.	1.4	60

#	Article	IF	Citations
55	Histiocytosis. Lancet, The, 2021, 398, 157-170.	13.7	58
56	Circulating cellâ€free BRAF^{V600E} as a biomarker in children with Langerhans cell histiocytosis. British Journal of Haematology, 2017, 178, 457-467.	2.5	57
57	Vinblastine chemotherapy in adult patients with langerhans cell histiocytosis: a multicenter retrospective study. Orphanet Journal of Rare Diseases, 2017, 12, 95.	2.7	57
58	Epidemiology of Congenital Neutropenia. Hematology/Oncology Clinics of North America, 2013, 27, 1-17.	2.2	55
59	Risk and benefit of treatment of severe chronic neutropenia with granulocyte colony-stimulating factor. Seminars in Hematology, 2002, 39, 134-140.	3.4	54
60	Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. British Journal of Haematology, 2018, 183, 608-617.	2.5	54
61	Efficacy of vinblastine in central nervous system Langerhans cell histiocytosis: a nationwide retrospective study. Orphanet Journal of Rare Diseases, 2011, 6, 83.	2.7	48
62	Clinical spectrum and long-term follow-up of 14 cases with G6PC3 mutations from the French severe congenital neutropenia registry. Orphanet Journal of Rare Diseases, 2014, 9, 183.	2.7	48
63	EFL1 mutations impair eIF6 release to cause Shwachman-Diamond syndrome. Blood, 2019, 134, 277-290.	1.4	48
64	Herpes-Virus Infection in Patients with Langerhans Cell Histiocytosis: A Case-Controlled Sero-Epidemiological Study, and In Situ Analysis. PLoS ONE, 2008, 3, e3262.	2.5	48
65	Estimation of the Radiation Dose From Thoracic CT Scans in a Cystic Fibrosis Population. Chest, 2007, 132, 1233-1238.	0.8	46
66	Somatic genetic rescue of a germline ribosome assembly defect. Nature Communications, 2021, 12, 5044.	12.8	44
67	Tetralogy of Fallot is an Uncommon Manifestation of Warts, Hypogammaglobulinemia, Infections, and Myelokathexis Syndrome. Journal of Pediatrics, 2012, 161, 763-765.	1.8	37
68	New somatic BRAF splicing mutation in Langerhans cell histiocytosis. Molecular Cancer, 2017, 16, 115.	19.2	37
69	Lymphoid differentiation of hematopoietic stem cells requires efficient Cxcr4 desensitization. Journal of Experimental Medicine, 2017, 214, 2023-2040.	8.5	36
70	Thymus and mediastinal node involvement in childhood langerhans cell histiocytosis: Longâ€term followâ€up from the French national cohort. Pediatric Blood and Cancer, 2013, 60, 1759-1765.	1.5	35
71	Severe chronic primary neutropenia in adults: report on a series of 108 patients. Blood, 2015, 126, 1643-1650.	1.4	32
72	Langerhans cell histiocytosis: a clinical update. , 2005, , 95-129.		30

#	Article	IF	Citations
73	18F-FDG PET in neurodegenerative Langerhans cell histiocytosis. Journal of Neurology, 2008, 255, 575-580.	3.6	30
74	High frequency of clonal hematopoiesis in Erdheim-Chester disease. Blood, 2021, 137, 485-492.	1.4	30
75	Inherited GATA2 Deficiency Is Dominant by Haploinsufficiency and Displays Incomplete Clinical Penetrance. Journal of Clinical Immunology, 2021, 41, 639-657.	3.8	30
76	Common cancer-associated PIK3CA activating mutations rarely occur in Langerhans cell histiocytosis. Blood, 2015, 125, 2448-2449.	1.4	28
77	Highly sensitive methods are required to detect mutations in histiocytoses. Haematologica, 2019, 104, e97-e99.	3.5	27
78	Heterozygous variants of CLPB are a cause of severe congenital neutropenia. Blood, 2022, 139, 779-791.	1.4	25
79	Is pegfilgrastim safe and effective in congenital neutropenia? An analysis of the French Severe Chronic Neutropenia registry. Pediatric Blood and Cancer, 2009, 53, 1068-1073.	1.5	24
80	Neurological findings and genetic alterations in patients with Kostmann syndrome and HAX1 mutations. Pediatric Blood and Cancer, 2014, 61, 1041-1048.	1.5	24
81	HSCT may lower leukemia risk in ELANE neutropenia: a beforeâ€“after study from the French Severe Congenital Neutropenia Registry. Bone Marrow Transplantation, 2020, 55, 1614-1622.	2.4	24
82	Application of wholeâ€exome sequencing to unravel the molecular basis of undiagnosed syndromic congenital neutropenia with intellectual disability. American Journal of Medical Genetics, Part A, 2017, 173, 62-71.	1.2	23
83	Vemurafenib as first line therapy in BRAF-mutated Langerhans cell histiocytosis. Journal of the American Academy of Dermatology, 2015, 73, e29-e30.	1.2	22
84	Central nervous system involvement in Erdheim-Chester disease. Neurology, 2020, 95, e2746-e2754.	1.1	22
85	Cladribine improves lung cysts and pulmonary function in a child with histiocytosis. European Respiratory Journal, 2015, 45, 831-833.	6.7	20
86	How to differentiate congenital from noncongenital chronic neutropenia at the first medical examination? Proposal of score: A pilot study from the French Severe Chronic Neutropenia registry. Pediatric Blood and Cancer, 2017, 64, e26722.	1.5	17
87	Neutropenia in congenital nephrotic syndrome of the Finnish type: role of urinary ceruloplasmin loss. Blood, 2009, 113, 4820-4821.	1.4	16
88	CXCR4 signaling controls dendritic cell location and activation at steady state and in inflammation. Blood, 2021, 137, 2770-2784.	1.4	16
89	Langerhans cell histiocytosis and associated malignancies: A retrospective analysis of 270 patients. European Journal of Cancer, 2022, 172, 138-145.	2.8	15
90	Management of Gorham Stout disease with skull-base defects: Case series of six children and literature review. International Journal of Pediatric Otorhinolaryngology, 2019, 124, 152-156.	1.0	14

#	Article	IF	Citations
91	Childhood pulmonary Langerhans cell histiocytosis: a comprehensive clinical-histopathological and BRAFV600E mutation study from the French national cohort. Human Pathology, 2019, 89, 51-61.	2.0	14
92	Longâ€term followâ€up of children with risk organâ€negative Langerhans cell histiocytosis after 2â€chlorodeoxyadenosine treatment. British Journal of Haematology, 2020, 191, 825-834.	2.5	14
93	Childhood Langerhans cell histiocytosis with severe lung involvement: a nationwide cohort study. Orphanet Journal of Rare Diseases, 2020, 15, 241.	2.7	14
94	Longâ€term efficacy and safety of 2CdA (cladribine) in extraâ€pulmonary adultâ€onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. British Journal of Haematology, 2020, 189, 869-878.	2.5	14
95	PTPN11 mutations in canine and human disseminated histiocytic sarcoma. International Journal of Cancer, 2020, 147, 1657-1665.	5.1	14
96	Respiratory distress and sudden death of a patient with GSDIb chronic neutropenia: possible role of pegfilgrastim. Haematologica, 2009, 94, 1175-1177.	3.5	13
97	Cardiomyopathies and congenital heart diseases in Shwachmanâ€“Diamond syndrome: A national survey. International Journal of Cardiology, 2013, 167, 1048-1050.	1.7	13
98	The cognitive spectrum in neurodegenerative Langerhans cell histiocytosis. Journal of Neurology, 2014, 261, 1537-1543.	3.6	13
99	Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort. Molecular Genetics and Metabolism Reports, 2020, 23, 100581.	1.1	12
100	Renal Carcinoma in a Patient With Glycogen Storage Disease Ib Receiving Long-term Granulocyte Colony-Stimulating Factor Therapy. The American Journal of Pediatric Hematology/oncology, 2000, 22, 188-189.	1.3	12
101	Cholesteatoma Secondary to Temporal Bone Involvement by Langerhans Cell Histiocytosis. Otology and Neurotology, 2009, 30, 190-193.	1.3	11
102	Recurrent bacterial infections, but not fungal infections, characterise patients with ELANEâ€related neutropenia: a French Severe Chronic Neutropenia Registry study. British Journal of Haematology, 2021, 194, 908-920.	2.5	11
103	Identification of biallelic germline variants of SRP68 in a sporadic case with severe congenital neutropenia. Haematologica, 2021, 106, 1216-1219.	3.5	10
104	Postâ€COVIDâ€19 severe neutropenia. Pediatric Blood and Cancer, 2021, 68, e28866.	1.5	9
105	TP53 mutations: the dawn of Shwachman clones. Blood, 2018, 131, 376-377.	1.4	8
106	Additive Prognostic Impact of Gastrointestinal Involvement in Severe Multisystem Langerhans Cell Histiocytosis. Journal of Pediatrics, 2021, 237, 65-70.e3.	1.8	8
107	Chest computed tomography findings for a cohort of children with pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2020, 67, e28496.	1.5	7
108	Distinctive vasculopathy with systemic involvement due to levamisole long-term therapy: aÂcase report. Journal of Medical Case Reports, 2018, 12, 209.	0.8	6

#	Article	IF	Citations
109	Cutaneous adverse events in children treated with vemurafenib for refractory BRAF^{V600E} mutated Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2021, 68, e29140.	1.5	6
110	Chronic neutropenia: how best to assess severity and approach management?. Expert Review of Hematology, 2021, 14, 945-960.	2.2	6
111	Early-onset hypogammaglobulinemia: A survey of 44 patients. Journal of Allergy and Clinical Immunology, 2015, 136, 1097-1099.e2.	2.9	5
112	A circulating subset of BRAF^{V600E}â€positive cells in infants with highâ€risk Langerhans cell histiocytosis treated with BRAF inhibitors. British Journal of Haematology, 2021, 194, 745-749.	2.5	5
113	Cladribineâ€related immunosuppression may have fostered graftâ€versusâ€host disease after lung transplant for pulmonary Langerhans cell histiocytosis. Pediatric Blood and Cancer, 2019, 66, e27477.	1.5	4
114	Shwachmanâ€Diamond syndrome and solid tumors: Three new patients from the French Registry for Severe Chronic Neutropenia and literature review. Pediatric Blood and Cancer, 2021, 68, e29071.	1.5	4
115	Is G-CSF-mobilized peripheral stem cell harvest harmful?. Pediatric Blood and Cancer, 2007, 48, 595-595.	1.5	3
116	Severe Transitory Neonatal Neutropenia Associated with Maternal Autoimmune or Idiopathic Neutropenia. Journal of Clinical Immunology, 2019, 39, 200-206.	3.8	3
117	How Many Patients Have Congenital Neutropenia? a Population-Based Estimation from the Nationwide French Severe Chronic Neutropenia Registry. Blood, 2020, 136, 40-41.	1.4	3
118	Eye movement abnormalities in neurodegenerative langerhans cell histiocytosis. Neurological Sciences, 2022, 43, 6539-6546.	1.9	3
119	Neurodegeneration in histiocytoses might start in utero. Lancet Neurology, The, 2017, 16, 953-954.	10.2	2
120	Congenital and Acquired Chronic Neutropenias: Challenges, Perspectives and Implementation of the EuNetâ€INNOCHRON Action. HemaSphere, 2020, 4, e406.	2.7	2
121	Establishment of MOS-SF36 percentile ranks in the general youth French population. BMC Psychology, 2022, 10, 74.	2.1	2
122	Diabetes Mellitus, Extreme Insulin Resistance, and Hypothalamic-Pituitary Langerhans Cells Histiocytosis. Case Reports in Endocrinology, 2019, 2019, 1-8.	0.4	1
123	Long-term outcome of severe paediatric pulmonary Langerhans cell histiocytosis: do not underestimate lung plasticity. BMJ Case Reports, 2021, 14, e241860.	0.5	1
124	Prognostic impact of pulmonary nodules diagnosed at initial presentation in patients with osteosarcoma. Pediatric Blood and Cancer, 2022, , e29725.	1.5	1
125	Atteintes ostÃ©oarticulaires au cours des histiocytoses. Revue Du Rhumatisme Monographies, 2019, 86, 120-125.	0.0	0
126	Langerhans cell histiocytosis with extensive lung destruction: Not always the worstâ€case scenario. Pediatric Pulmonology, 2021, 56, 327-328.	2.0	0

#	Article	IF	Citations
127	Langerhans cell histiocytosis in children: Correlation of BRAF status with clinical characteristic.. Journal of Clinical Oncology, 2015, 33, 10003-10003.	1.6	0
128	EFL1 deficiency: a little is better than nothing. Blood, 2021, 138, 2016-2018.	1.4	0